# Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

> **NCT02240407** · PHASE1 · COMPLETED · sponsor: **University of Florida** · enrollment: 2 (actual)

## Conditions studied

- Pompe Disease

## Interventions

- **GENETIC:** Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase
- **DRUG:** Rapamycin
- **OTHER:** saline
- **DRUG:** Rituxan
- **DRUG:** Diphenhydramine
- **DRUG:** Acetaminophen
- **DRUG:** Lidocaine
- **DRUG:** LMX 4 Topical Cream

## Key facts

- **NCT ID:** NCT02240407
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2021-08-26
- **Final completion:** 2021-08-26
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2022-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02240407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02240407, "Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02240407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*